Errors in Table 2 - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Corrections Noted in Table 2 of the Study on Ixekizumab and Tirzepatide for Psoriasis in Adults with Overweight or Obesity

  • July 1, 2026

Share

Objective:

To address inaccuracies identified in Table 2 of the original study on Ixekizumab and Tirzepatide.

Approach:
  • Correction Details: Baseline PASI was corrected from 'mean (SD)' to 'mean (SE),' and metabolic endpoints were reclassified as 'mean (SE)' to ensure accurate reporting.
Key Findings:
  • Corrections were made to the baseline PASI measurements, which were previously reported inaccurately.
  • Table 2 contained inaccuracies that have now been rectified.
Interpretation:

The article has been rectified online to reflect accurate statistical measures.

Conclusion:

Corrections to the baseline PASI and metabolic endpoints have been made to ensure the accuracy of the reported data.

Original Source(s)

Errors in Table 2

  • July 1, 2026

Related Content

Triglycerides Linked to Psoriasis Risk

Genetically predicted triglyceride levels were associated with higher odds of psoriasis, while genetically predicted total fatty acid levels were not, in a two-sample Mendelian randomization analysis.

Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn’s disease

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.